DoD Melanoma Research Program anticipated funding opportunities for FY23

FDA grants Replimune’s RP1 an accelerated approval on third submission after 10:3 vote from advisory committee
Amid political outcry, advisors accept weak data and give sponsor a chance to complete phase III trial

FDA has granted an accelerated approval to RP1 (vusolimogene oderparepvec) following the agency’s Cellular, Tissue, and Gene Therapies Advisory Committee’s 10:3 vote in support of the biologic in combination with nivolumab for the treatment of advanced melanoma in patients who have progressed on prior anti-PD-1 therapy.

August 07, 2026

Vol.52 No.31

By Jacquelyn Cobb and Paul Goldberg

Drugs & Targets

After two CRLs, FDA advisory committee votes in favor of Replimune’s melanoma drug

FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee voted 10:3 in favor of Replimune’s Biologics License Application for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma.

July 31, 2026

Vol.52 No.30

In Brief

The V Foundation announces recipients of the 2026 Breaking Barriers in Cancer Research Award

The V Foundation for Cancer Research, a top-rated cancer research charity, announced $11.2 million in funding awarded to 14 scientists through its 2026 Breaking Barriers in Cancer Research Award program.

July 24, 2026

Vol.52 No.29

In Brief

Sylvester’s Marlon Wong receives Gabrielle’s Angel Foundation grant to study CIPN

Marlon L. Wong, associate professor of clinical physical therapy at the University of Miami Miller School of Medicine, was awarded a grant from Gabrielle’s Angel Foundation for Cancer Research. The three-year, $225,000 award will support research focused on improving quality of life for patients living with chemotherapy-induced peripheral neuropathy and other long-term effects of cancer treatment.

July 24, 2026

Vol.52 No.29

Funding Opportunities

Binaytara invites abstract applications for National Summit on Hematologic Cancers’ Hematologic Innovation Challenge

Early-career hematologists will have the opportunity to compete for a share of $250,000 in research funding at Binaytara’s 2026 National Summit on Hematologic Cancers to be held Oct. 16-17 at Music City Center in Nashville, TN.

July 17, 2026

Vol.52 No.28

Capitol Hill

OMB’s plan to increase political control of science faces stiff opposition on Capitol Hill

The Trump administration has a fight on its hands as it pushes forward with a plan to exert greater political control over government funding of science.

July 10, 2026

Vol.52 No.27

By Paul Goldberg

DoD Melanoma Research Program anticipated funding opportunities for FY23

YOU MAY BE INTERESTED IN

FDA grants Replimune’s RP1 an accelerated approval on third submission after 10:3 vote from advisory committee
Amid political outcry, advisors accept weak data and give sponsor a chance to complete phase III trial

After two CRLs, FDA advisory committee votes in favor of Replimune’s melanoma drug

The V Foundation announces recipients of the 2026 Breaking Barriers in Cancer Research Award

Sylvester’s Marlon Wong receives Gabrielle’s Angel Foundation grant to study CIPN

Binaytara invites abstract applications for National Summit on Hematologic Cancers’ Hematologic Innovation Challenge

OMB’s plan to increase political control of science faces stiff opposition on Capitol Hill

Renew today!

Subscriber content

Never miss an issue!

Login

DoD Melanoma Research Program anticipated funding opportunities for FY23

YOU MAY BE INTERESTED IN

FDA grants Replimune’s RP1 an accelerated approval on third submission after 10:3 vote from advisory committeeAmid political outcry, advisors accept weak data and give sponsor a chance to complete phase III trial

After two CRLs, FDA advisory committee votes in favor of Replimune’s melanoma drug

The V Foundation announces recipients of the 2026 Breaking Barriers in Cancer Research Award

Sylvester’s Marlon Wong receives Gabrielle’s Angel Foundation grant to study CIPN

Binaytara invites abstract applications for National Summit on Hematologic Cancers’ Hematologic Innovation Challenge

OMB’s plan to increase political control of science faces stiff opposition on Capitol Hill

Never miss an issue!

Login

FDA grants Replimune’s RP1 an accelerated approval on third submission after 10:3 vote from advisory committee
Amid political outcry, advisors accept weak data and give sponsor a chance to complete phase III trial